ArticleJournal of inflammation research2025
An Exploratory Study on a Potential Biomarker for Seizures in Autoimmune Encephalitis.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Peripheral Inflammatory Biomarkers in Chronic Autoimmune-Associated Epilepsy: An Exploratory Case-Control Study.Biomolecules · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Autoimmune encephalitis (AE) is a severe neurological disorder often associated with seizures, but the risk factors for seizures in AE remain unclear. This study aimed to compare the clinical features and laboratory results between AE patients with and without seizures, focusing on the potential role of peripheral blood (PB) eosinophil counts as a predictive biomarker for seizures. Methods: A retrospective cohort study was conducted on 106 AE patients admitted to the First Affiliated Hospital of Anhui Medical University. Patients were divided into two groups based on seizure presence: the seizure group (n=48) and the non-seizure group (n=58). A control group of 34 patients with AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) was included. A control group of 34 patients with AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD), a demyelinating condition not typically associated with neuronal autoantibodies or seizures, was included for comparison. Clinical features and laboratory results were compared, with statistical analysis including univariate and multivariate logistic regression, as well as receiver operating characteristic (ROC) curve analysis. Results: The seizure group had significantly higher rates of prodromal symptoms, impaired consciousness, cerebrospinal fluid (CSF) protein (>0.45g/L) and CSF glucose levels, blood-brain barrier (BBB) dysfunction, and PB eosinophil counts compared to the non-seizure and control groups (all P<0.05). PB eosinophil counts were identified as an independent predictor of seizures. Conclusion: Specific clinical and laboratory features are closely associated with seizures in AE. Increased PB eosinophil counts may serve as a novel biomarker for seizure risk in AE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.